We have been developing biochip technologies and products for 10 years in collaboration with leading research hospitals in China to satisfy unmet demands from hospital bedsides.The products that have been certified by China SFDA including a DNA microarray analyzing nine mutations in four human genomic and mitochondrial genes account for approximately 80% of the causes of inherited deafness, including susceptibility to deafness induced by exposure to aminoglycoside antibiotics, and a protein array for autoimmune disease diagnosis.In addition, two chips that can provide rapid sample-to-answer results in only 6 hours have also been developed, one chip identifies 17 different mycobacteria and the second chip detects the resistance to two first line drugs, Rifampicin and Isoniazid.These two multi-facet TB tests are certified by both the China SFDA and the European Community (CE mark).A number of other close to market products include a HBV drug resistance detection array for Lamivudine and Adefovir, a microfluidic chip for the identification of 12 major bacterial-associated respiratory infections in 2 hours.Array-based evaluation of metastasis for breast cancer and the assessment of patients response to chemotherapy will be discussed.Active biochip technologies for fertility and reproductive health will also be presented.